Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qing-Re-Liang-Xue Decoction for Psoriasis Vulgaris
NCT04994951Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of qing-re-liang-xue decoction in Psoriasis vulgaris (PV) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Clinical Response defined by Psoriasis Area Severity Index at 10 weeks. Status: unknown.
02
Drugs
qing-re-liang-xue decoction
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT04994951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994951.